Search results
Results from the WOW.Com Content Network
Repaglinide (trade name Prandin) [2] gained US Food and Drug Administration approval in 1997. Other drugs in this class include nateglinide (Starlix) [ 3 ] and mitiglinide (Glufast). Side effects
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [ 1 ]
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [ 1 ] [ 2 ] It is regarded as a second-line option compared to metformin , due to metformin's well-established safety and efficacy. [ 1 ]
A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than those taking DPP-4 drugs.
If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced the powerful effects of this weight loss medication. But what happens when you decide to stop taking semaglutide?
Due to longstanding pushback and controversial health studies surrounding the ingredient, many processed food manufacturers have already shifted away from using Red Dye No. 3, opting instead for ...
Toby Fischer lives in South Dakota, where just 27 doctors are certified to prescribe buprenorphine -- a medication that blunts the symptoms of withdrawal from heroin and opioid painkillers. A Huffington Post analysis of government data found nearly half of all counties in America don't have such a certified physician. So every month, Fischer and his mother drive to Colorado to pick up their ...
A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". [1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing ...